BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9469479)

  • 1. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production.
    Eigler A; Siegmund B; Emmerich U; Baumann KH; Hartmann G; Endres S
    J Leukoc Biol; 1998 Jan; 63(1):101-7. PubMed ID: 9469479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of tumor necrosis factor-alpha production by interleukin-10 is enhanced by cAMP-elevating agents.
    Siegmund B; Eigler A; Moeller J; Greten TF; Hartmann G; Endres S
    Eur J Pharmacol; 1997 Feb; 321(2):231-9. PubMed ID: 9063693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids.
    Sinha B; Semmler J; Eisenhut T; Eigler A; Endres S
    Eur J Immunol; 1995 Jan; 25(1):147-53. PubMed ID: 7843225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM; Barnes PJ; Giembycz MA
    Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of TNF-alpha production in human mononuclear cells by an adenosine kinase inhibitor.
    Eigler A; Matschke V; Hartmann G; Erhardt S; Boyle D; Firestein GS; Endres S
    J Leukoc Biol; 2000 Jul; 68(1):97-103. PubMed ID: 10914495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM; Barnes PJ; Meja K; Giembycz MA
    Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-alpha synthesis.
    Greten TF; Sinha B; Haslberger C; Eigler A; Endres S
    Eur J Pharmacol; 1996 Mar; 299(1-3):229-33. PubMed ID: 8901027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis.
    Foey AD; Field S; Ahmed S; Jain A; Feldmann M; Brennan FM; Williams R
    Arthritis Res Ther; 2003; 5(6):R317-28. PubMed ID: 14680506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenaline enhances LPS-induced IL-10 synthesis: evidence for protein kinase A-mediated pathway.
    Siegmund B; Eigler A; Hartmann G; Hacker U; Endres S
    Int J Immunopharmacol; 1998; 20(1-3):57-69. PubMed ID: 9717082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of IL-15-stimulated TNF-alpha production by rolipram.
    Kasyapa CS; Stentz CL; Davey MP; Carr DW
    J Immunol; 1999 Sep; 163(5):2836-43. PubMed ID: 10453029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung.
    Gonçalves de Moraes VL; Singer M; Vargaftig BB; Chignard M
    Br J Pharmacol; 1998 Feb; 123(4):631-6. PubMed ID: 9517381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of tumour necrosis factor-alpha in tissue culture of rat caecum: lack of suppression by phosphodiesterase inhibitors and prostanoids.
    Greten TF; Moeller J; Feldmeier H; Eigler A; Endres S
    Eur J Gastroenterol Hepatol; 1996 Jul; 8(7):679-84. PubMed ID: 8853258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor.
    Prabhakar U; Lipshutz D; Bartus JO; Slivjak MJ; Smith EF; Lee JC; Esser KM
    Int J Immunopharmacol; 1994 Oct; 16(10):805-16. PubMed ID: 7843852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of tumor necrosis factor alpha production by cAMP in human monocytes: dissociation with mRNA level and independent of interleukin-10.
    Shames BD; McIntyre RC; Bensard DD; Pulido EJ; Selzman CH; Reznikov LL; Harken AH; Meng X
    J Surg Res; 2001 Aug; 99(2):187-93. PubMed ID: 11469886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rolipram, salbutamol and prostaglandin E2 suppress TNFalpha release from human monocytes by activating Type II cAMP-dependent protein kinase.
    Seldon PM; Meja KK; Giembycz MA
    Pulm Pharmacol Ther; 2005; 18(4):277-84. PubMed ID: 15777610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
    Souness JE; Griffin M; Maslen C; Ebsworth K; Scott LC; Pollock K; Palfreyman MN; Karlsson JA
    Br J Pharmacol; 1996 Jun; 118(3):649-58. PubMed ID: 8762090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
    Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
    Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages.
    Kambayashi T; Jacob CO; Zhou D; Mazurek N; Fong M; Strassmann G
    J Immunol; 1995 Nov; 155(10):4909-16. PubMed ID: 7594495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential regulation of TNF-alpha, IL-6 and IL-10 in UVB-irradiated human keratinocytes via cyclic AMP/protein kinase A pathway.
    Grandjean-Laquerriere A; Le Naour R; Gangloff SC; Guenounou M
    Cytokine; 2003 Aug 21-Sep 7; 23(4-5):138-49. PubMed ID: 12967650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide.
    Greten TF; Eigler A; Sinha B; Moeller J; Endres S
    Int J Immunopharmacol; 1995 Jul; 17(7):605-10. PubMed ID: 8586489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.